Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
biote
BTMD
biote
Aging Population And Personalized Medicine Will Expand Global Care Networks
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 5 Analysts
Published
19 May 25
Updated
23 Jul 25
0
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
US$8.00
64.0% undervalued
intrinsic discount
23 Jul
US$2.88
Loading
1Y
-47.5%
7D
-26.0%
Author's Valuation
US$8.0
64.0% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
US$8.0
64.0% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-10m
199m
2019
2021
2023
2025
2027
2028
Revenue US$178.8m
Earnings US$14.9m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
6.88%
Pharma revenue growth rate
1.01%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$14.91m
Earnings '28
x
21.34x
PE Ratio '28
=
US$318.12m
Market Cap '28
US$318.12m
Market Cap '28
/
33.01m
No. shares '28
=
US$9.64
Share Price '28
US$9.64
Share Price '28
Discounted to 2025 @ 6.40% p.a.
=
US$8.00
Fair Value '25